Sanofi CEO Paul Hudson says his company is the Big Pharma 'least exposed' to generics this decade

Among its Big Pharma peers, Sanofi is the pharma stock “least exposed” to generic competition through 2030, CEO Paul Hudson said on an investor call Thursday. That’s because Aubagio’s plunge off the patent cliff in 2023 marks Sanofi’s “last meaningful [loss of exclusivity] this decade,” the helmsman explained. Further, Sanofi expects the continued momentum behind Dupixent to more than make up for its Aubagio sales slide, Hudson said.